Skip to main content

Advertisement

SpringerLink
Log in

How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Nipple-sparing mastectomy (NSM) is now routinely offered to BRCA mutation carriers for risk reduction. We assessed the rates of ipsilateral cancer events after prophylactic and therapeutic NSM in BRCA1 and BRCA2 mutation carriers.

Methods

BRCA1 and BRCA2 mutation carriers undergoing NSM from October 2007 to June 2019 were identified in a single-institution prospective database, with variants of unknown significance being excluded. Patient, tumor, and outcomes data were collected. Follow-up analysis was by cumulative breast-years (total years of follow-up of each breast) and woman-years (total years of follow-up of each woman).

Results

Overall, 307 BRCA1 and BRCA2 mutation carriers (160 BRCA1, mean age 41.4 years [range 21–65]; and 147 BRCA2, mean age 43.8 years [range 23–65]) underwent 607 NSMs, with a median follow-up of 42 months (range 1–143). 388 bilateral prophylactic NSMs had 744 cumulative woman-years of follow-up, with no new cancers seen (< 0.0013 new cancers per woman-years); 251 BRCA1 prophylactic NSMs had 1034 cumulative breast-years of follow-up, with no new ipsilateral cancers seen (< 0.0010 per breast-year); 66 BRCA1 therapeutic NSMs had 328 cumulative breast-years of follow-up, with one ipsilateral cancer recurrence not directly involving the nipple or areola (0.0030 per breast-year); 237 BRCA2 prophylactic NSMs had 926 cumulative breast-years of follow-up, with no new ipsilateral cancers seen (< 0.0011 per breast-year); and 53 BRCA2 therapeutic NSMs had 239 cumulative breast-years of follow-up, with two ipsilateral recurrent cancers, neither of which directly involved the nipple or areola (0.0084 per breast-year).

Conclusions

The risk of new ipsilateral breast cancers is extremely low after NSM in BRCA1 and BRCA2 mutation carriers. NSM is an effective risk-reducing strategy for BRCA gene mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.

    Article  CAS  Google Scholar 

  2. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77–84.

    Article  CAS  Google Scholar 

  3. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–62.

    Article  Google Scholar 

  4. Rusby JE, Brachtel EF, Michaelson JS, Koerner FC, Smith BL. Breast duct anatomy in the human nipple: three dimensional patterns and clinical implications. Breast Cancer Res Treat. 2007;106:171–9.

    Article  Google Scholar 

  5. Rusby JE, Brachtel EF, Taghian AG, Michaelson JS, Koerner FC, Smith BL. Microscopic anatomy within the nipple: Implications for nipple sparing mastectomy. Am J Surg. 2007;194:433–7.

    Article  Google Scholar 

  6. Rusby JE, Kirstein LJ, Brachtel EF, et al. Nipple-sparing mastectomy: lessons from ex vivo procedures. Breast J. 2008;14(5):464–70.

    Article  Google Scholar 

  7. Coopey SB, Tang R, Lei L, et al. Increasing Eligibility for Nipple-Sparing Mastectomy. Ann Surg Oncol. 2013;20:3218–22.

    Article  Google Scholar 

  8. Petit JY, Veronisi U, Orecchia R, et al. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat. 2009;117:333–8.

    Article  CAS  Google Scholar 

  9. Smith BL, Tang R, Rai U, et al. Oncologic safety of nipple-sparing mastectomy in women with breast cancer. J Am Coll Surg. 2017;225(3):361–5.

    Article  Google Scholar 

  10. Valero MG, Moo T, Muhson S, et al. Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer. Br J Surg. 2020;107:1307–12.

    Article  CAS  Google Scholar 

  11. Peled AW, Irwin CS, Hwang ES, et al. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 2014;21(1):37–41.

    Article  Google Scholar 

  12. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633–7.

    Article  CAS  Google Scholar 

  13. Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015;22(2):370–6.

    Article  Google Scholar 

  14. Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg. 2018;153(2):123–9.

    Article  Google Scholar 

  15. Manning AT, Wood C, Eaton A, et al. Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance. Br J Surg. 2015;102(11):1354–9.

    Article  CAS  Google Scholar 

  16. Colwell A, Gadd M, Smith BL, Austen W. An inferolateral approach to nipple-sparing mastectomy: optimizing mastectomy and reconstruction. Ann Plast Surg. 2010;65(2):140–3.

    Article  CAS  Google Scholar 

  17. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies [published erratum appears in Am J Hum Genet. 2003 Sep;73(3):709]. Am J Hum Genet. 2003;72(5):1117–30.

    Article  CAS  Google Scholar 

  18. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–89.

    Article  CAS  Google Scholar 

  19. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.

    Article  CAS  Google Scholar 

  20. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [published errata appear in JAMA. 2006 Dec;296(24):2926; and JAMA. 2007 Sep;298(9):973. JAMA. 2006;295(23):2727–41.

  21. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67–75.

    Article  CAS  Google Scholar 

  22. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women [published erratum appears in N Engl J Med. 2011 Oct;365(14):1361]. N Engl J Med. 2011;364(25):2381–91.

    Article  CAS  Google Scholar 

  23. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA. 2001;286(18):2251–6.

    Article  CAS  Google Scholar 

  24. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846–53.

    Article  CAS  Google Scholar 

  25. Bayraktar S, Glück S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat. 2012;135(2):355–66.

    Article  CAS  Google Scholar 

  26. Rusby JE, Smith BL, Gui GPH. Nipple sparing mastectomy. Br J Surg. 2010;97:305–16.

    Article  CAS  Google Scholar 

  27. Smith BL, Coopey SB. Nipple-sparing mastectomy. Adv Surg. 2018;52(1):113–26.

    Article  Google Scholar 

  28. Frasson AL, Lichtenfels M, de Souza AAB, et al. Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients. Breast Cancer Res Treat. 2020;181(1):69–75.

    Article  CAS  Google Scholar 

  29. Henriquez A, Garstka M, Kelly BR, et al. Beyond BRCA: oncologic safety of nipple-sparing mastectomy in other risk gene mutation carriers [abstract]. Presented at the society of surgical oncology 2021 virtual annual cancer symposium, 18–19 March 2021.

  30. Kelly BR, Korotkin J, Smith BL, et al. Nipple-sparing mastectomy versus skin-sparing mastectomy: short and long-term patient satisfaction [abstract]. Presented at the American society of breast surgeons 2020 virtual scientific session, 29 April–3 May 2020.

Download references

Funding

No external sources of financial or material support were used for this study.

Author information

Authors and Affiliations

  1. Breast Program, Division of Surgical Oncology, Massachusetts General Hospital, MGH Center for Breast Cancer, Boston, MA, USA

    Meghan Garstka MD, MS, Anthony Henriquez AB, Bridget N. Kelly BA, Alexandra Webster BS, Jasmine A. Khubchandani MD, Kevin Hughes MD, Anvy Nguyen MD, Tawakalitu Oseni MD, Michelle Specht MD, Suzanne B. Coopey MD, Michele A. Gadd MD & Barbara L. Smith MD, PhD

Authors
  1. Meghan Garstka MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony Henriquez AB
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bridget N. Kelly BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandra Webster BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jasmine A. Khubchandani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kevin Hughes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anvy Nguyen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tawakalitu Oseni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michelle Specht MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Suzanne B. Coopey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michele A. Gadd MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Barbara L. Smith MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara L. Smith MD, PhD.

Ethics declarations

DISCLOSURES

Kevin Hughes receives honoraria from Hologic (surgical implant for radiation planning with breast conservation and wire-free breast biopsy) and Myriad Genetics, and is a founder of and has a financial interest in CRA Health (formerly Hughes RiskApps, cancer risk assessment software), which was recently acquired by Volpara (breast density and cancer risk assessment company). He is the co-creator of Ask2Me.Org. Kevin Hughes’ interests were reviewed, and are managed by, Massachusetts General Hospital and Mass General Brigham Healthcare in accordance with their conflict of interest policies. Meghan Garstka, Anthony Henriquez, Bridget N. Kelly, Alexandra Webster, Jasmine A. Khubchandani, Anvy Nguyen, Tawakalitu Oseni, Michelle Specht, Suzanne B. Coopey, Michele A. Gadd, and Barbara L. Smith have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garstka, M., Henriquez, A., Kelly, B.N. et al. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?. Ann Surg Oncol 28, 5657–5662 (2021). https://doi.org/10.1245/s10434-021-10445-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10445-9

Search

Navigation